Litcius/Paper detail

Botulinum toxin type A for controlling bruxism assessed with computerized occlusal analysis: A pilot study

Nícea B. Pardo, Robert B. Kerstein, Mario C. Júnior, Leila Soares Ferreira, Márcio Abrahão

2020CRANIO®18 citationsDOI

Abstract

Objective: To assess botulinum toxin-A (BTX-A) on mandibular movements and bite force (BF%) in bruxism.Methods: Ten bruxers were divided into 2 groups based on BF% imbalance (G1: >10%, G2: <10%). BTX-A 140U was total injected into the masseter and temporalis muscles. A T-Scan® recorded BF%, occlusion time (OT), right, left, and protrusive disclusion time (DT) before administering BTX-A, as well as 15, 45, 90, and 120 days after injection.Results: The Friedman and Wilcoxon tests found significant differences in BF% in G1 subjects at 15 days (p = 0.028 s), OT at 90 (p = 0.043 s), and 120 (p = 0.027 s) days, DTR at 90 (p = 0.046 s) and 120 (p = 0.028 s) days, DTL at 15 (p = 0.043 s) and 90 (p = 0.027 s) days, and DTP 45–90 days (p = 0.043 s).Conclusion: BTX-A induced BF% starting at 15 days post-injection and influenced lateralities later.

Topics & Concepts

OcclusionMedicineMasseter muscleDental occlusionDentistryBotulinum toxinAnesthesiaOrthodonticsInternal medicineTemporomandibular Joint DisordersBotulinum Toxin and Related Neurological DisordersOropharyngeal Anatomy and Pathologies